Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT06377293

Effect of Dialysis-specific Therapeutic Diet on Biochemical Parameters in Dialysis Patients

In patients with kidney failure, disturbances in bone turnover, mineral metabolism, vascular calcification, uremia, inflammation, immunity, metabolomics, nutrition, and gut microbial metabolites are frequent. Unhealthy diet causes altered mineral metabolism, elevated uremic toxin level, immune dysregulation, metabolic abnormalities, inflammation, protein-energy wasting and dysbiosis. The investigators hypothesize that therapeutic diet intervention reverses these uremic complications and thereby reduces cardiovascular risk in patients with kidney failure. In this study, the investigators crafted 4-week dialysis-specific therapeutic diet to illustrate the clinical implications of therapeutic diet for dialysis patients.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Notify Me

Key information

About this study

In patients with kidney failure, disturbance in bone turnover and mineral metabolism, and nutritional deficiency is prevalent, leading to vascular calcification, uremia, inflammation, immune dysregulation, metabolic alteration, and gut microbial dysbiosis, and these abnormalities are associated with increased risk of fracture, extraskeletal or vascular calcification and cardiovascular mortality. It is well known that an unhealthy diet plays an important role in bone-mineral metabolism, uremia, inflammation, metabolomics, protein-energy wasting, and dysbiosis, and therefore nutritional therapy may help to manage these uremic complications to reduce cardiovascular risk in patients with kidney failure. Importantly, serum biomarkers regarding the above-mentioned abnormalities are acutely and closely related to food intake. To our knowledge, no study to date has examined the multifactorial effects of nutritional intervention on bone turnover, mineral metabolism, vascular calcification, uremia, inflammation, immunity, metabolomics, nutrition, and gut microbial metabolites in dialysis patients.

To examine the beneficial effects of nutritional intervention on clinical outcomes, the investigators crafted the dialysis-specific therapeutic diet which was characterized by adequate calorie and protein amounts, natural food ingredients with a low phosphorus-to-protein ratio, higher portions of plant-based food, and high fiber content. In the previous studies, the investigators found that the therapeutic diet rapidly reversed mineral abnormalities within the 1-week intervention period. Among these changes, reduction in serum phosphate level achieved in 2 days, modifications of intact parathyroid hormone (PTH) and calcium levels in 5 days, and reductions in intact and C-terminal fibroblast growth factor-23 (FGF23) levels in 7 days of therapeutic diet intervention. Although the therapeutic diet tended to change uremic toxin level, neither inflammatory nor nutritional markers changed which may be explained by short duration of intervention. It is of interest to know whether the therapeutic diet has a favorable effect on bone turnover, vascular calcification, and gut microbial dysbiosis. In this continuity planning, the investigators are therefore going to analyze the 4-week diet-induced changes in biomarkers regarding bone turnover, metabolites, vascular calcification, and gut microbial metabolites in addition to the previously assessed mineral metabolism, uremia, inflammation, immunity, and nutrition in dialysis patients.

This project aims to explore the multiple diverse effects of dialysis-specific healthy diet on the changes of bone turnover, mineral metabolism, vascular calcification, uremia, inflammation, immunity, metabolomics, nutrition, and gut microbial metabolites in dialysis patients. In contrast to the previous approaches, bone biomarkers for both of bone formation and bone resorption, vascular calcification biomarkers, and gut microbial metabolites will be comprehensively examined. Revealing a complex correlation between the nutritional factors and bone turnover, mineral metabolism, vascular calcification, uremia, inflammation, immunity, metabolomics, nutrition, and gut microbial dysbiosis, this project may shed light on understanding of diet-mediated bone-mineral and uremic homeostasis and uncover strategies of nutritional therapy. A better knowledge of diet-induced pathway on human body homeostasis may lead to new strategies for preventing fracture, vascular calcification or cardiovascular disease risk.

It is to conduct a randomized controlled trial with cross-over design at a dialysis unit of tertiary teaching hospital in Northern Taiwan. Subjects with aged older than 20 years, end-stage kidney disease (ESKD) undergoing maintenance dialysis for more than three months, having adequate dialysis and good dietary compliance will be included. Each participant will receive one study meal during the run-in period to give him or her the opportunity to assess whether he or she can successfully complete the study meals over the next 4 weeks, thus excluding participants who do not prefer the dietary intervention. Then, participants will be randomly assigned into two groups: group A and group B. Those in group A will receive study diet for 4 weeks, followed by 16-week washout period and then receive 4-week usual diet. The opposite order of diets will be prescribed in group B. The study meals are prepared in the hospital cafeteria. Dietary compositions of the study diets were analyzed before the start of the study. The study outcome measures are difference in change-from-baseline values of abnormal mineral metabolism, altered bone turnover, vascular calcification, uremic toxin production, immune dysregulation, metabolite alteration, nutrition, inflammation and gut microbial metabolites between the therapeutic diet and the usual diet.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Subjects with aged older than 20 years
  • End-stage kidney disease (ESKD) undergoing maintenance dialysis for more than three months
  • Must have adequate dialysis
  • Good dietary compliance

Exclusion criteria

  • Serum albumin level less than 2.5 g/dL
  • Hospitalization within the past 4 weeks
  • Prebiotics, probiotics, symbiotics or antibiotics use within the past 4 weeks
  • History of psychiatric disorders
  • Having mental retardation
  • Those who dislike of the study meals
  • Soft diet requirement
  • Vegetarian

Treatment and study plan

Dialysis-specific therapeutic diet

Other

A healthy diet for dialysis patients

Primary outcomes

  1. Concentrations of intact fibroblast growth factor 23 (pg/mL)

    Time frame: 4 weeks

    Difference in change-from-baseline intact fibroblast growth factor 23 (pg/mL) between therapeutic diet and usual diet

Secondary outcomes

  1. Concentrations of C-terminal fibroblast growth factor 23 (RU/mL)

    Time frame: 4 weeks

    Difference in change-from-baseline C-terminal fibroblast growth factor 23 (RU/mL) between therapeutic diet and usual diet

  2. Concentrations of phosphate (mg/dL)

    Time frame: 4 weeks

    Difference in change-from-baseline phosphate (mg/dL) between therapeutic diet and usual diet

  3. Concentrations of calcium (mg/dL)

    Time frame: 4 weeks

    Difference in change-from-baseline calcium (mg/dL) between therapeutic diet and usual diet

  4. Concentrations of intact parathyroid hormone (pg/mL)

    Time frame: 4 weeks

    Difference in change-from-baseline intact parathyroid hormone (pg/mL) between therapeutic diet and usual diet

  5. Concentrations of bone-specific alkaline phosphatase (μg/L)

    Time frame: 4 weeks

    Difference in change-from-baseline bone-specific alkaline phosphatase (μg/L) between therapeutic diet and usual diet

  6. Concentrations of procollagen-type 1 N-terminal-propeptide (P1NP) (ng/mL)

    Time frame: 4 weeks

    Difference in change-from-baseline procollagen-type 1 N-terminal-propeptide (P1NP) (ng/mL) between therapeutic diet and usual diet

  7. Concentrations of tartrate resistance acid phosphatase-5b (TRACP-5b) (mIU/ml)

    Time frame: 4 weeks

    Difference in change-from-baseline tartrate resistance acid phosphatase-5b (TRACP-5b) (mIU/ml) between therapeutic diet and usual diet

  8. Concentrations of alkaline phosphatase (ALP) (IU/L)

    Time frame: 4 weeks

    Difference in change-from-baseline alkaline phosphatase (ALP) (IU/L) between therapeutic diet and usual diet

  9. Concentrations of free indoxyl sulfate (mg/L)

    Time frame: 4 weeks

    Difference in change-from-baseline free indoxyl sulfate (mg/L) between therapeutic diet and usual diet

  10. Concentrations of free p-cresol sulfate (mg/L)

    Time frame: 4 weeks

    Difference in change-from-baseline free p-cresol sulfate (mg/L) between therapeutic diet and usual diet

  11. Concentrations of pre-albumin (g/dL)

    Time frame: 4 weeks

    Difference in change-from-baseline pre-albumin (g/dL) between therapeutic diet and usual diet

  12. Concentrations of albumin (g/dL)

    Time frame: 4 weeks

    Difference in change-from-baseline albumin (g/dL) between therapeutic diet and usual diet

  13. Concentrations of C-reactive protein (mg/dL)

    Time frame: 4 weeks

    Difference in change-from-baseline C-reactive protein (mg/dL) between therapeutic diet and usual diet

  14. Concentrations of quinolinate

    Time frame: 4 weeks

    Difference in change-from-baseline quinolinate between therapeutic diet and usual diet

  15. Concentrations of mesaconate

    Time frame: 4 weeks

    Difference in change-from-baseline mesaconate between therapeutic diet and usual diet

  16. Absolute number (per μl blood) of CD4+ (cluster of differentiation 4) T cells

    Time frame: 4 weeks

    Difference in change-from-baseline absolute number (per μl blood) of CD4+ (cluster of differentiation 4) T cells between therapeutic diet and usual diet

  17. Absolute number (per μl blood) of CD8+ (cluster of differentiation 8) T cells

    Time frame: 4 weeks

    Difference in change-from-baseline absolute number (per μl blood) of CD8+ (cluster of differentiation 8) T cells between therapeutic diet and usual diet

  18. Absolute number (per μl blood) of monocytes

    Time frame: 4 weeks

    Difference in change-from-baseline absolute number (per μl blood) of monocytes between therapeutic diet and usual diet

  19. Concentrations of fetuin-A (μg/ml)

    Time frame: 4 weeks

    Difference in change-from-baseline fetuin-A (μg/ml) between therapeutic diet and usual diet

  20. Concentrations of trimethylamine-N-oxide (TMAO) (μM)

    Time frame: 4 weeks

    Difference in change-from-baseline trimethylamine-N-oxide (TMAO) (μM) between therapeutic diet and usual diet

  21. Difference in change-from-baseline phosphate-binding equivalent dose (PBED) between therapeutic diet and usual diet

    Time frame: 4 weeks

    The phosphate-binder doses among the study participants will be compared by calculating the phosphate-binding equivalent dose (PBED) values as described by Daugirdas.

Sponsors and collaborators

Lead sponsor

Far Eastern Memorial Hospital

Other

Registry information

Official study title

Effects of Dialysis-specific Therapeutic Diet in Dialysis Patients

Important dates

Study start
2025
Primary completion
2025
Study completion
2029
First posted
Apr 22, 2024
Registry last updated
Aug 7, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.